Premium Nahrungsergänzungsmittel | artgerecht

PCSK9 Inhibitors: Mechanism, Uses & Side Effects

PCSK9 inhibitors are modern medicines used to lower LDL cholesterol levels. They are prescribed when statins are insufficient or not tolerated.

Regular tips about health Regular tips about health

Things worth knowing about "PCSK9 Inhibitors"

PCSK9 inhibitors are modern medicines used to lower LDL cholesterol levels. They are prescribed when statins are insufficient or not tolerated.

What Are PCSK9 Inhibitors?

PCSK9 inhibitors are a class of medications used to treat elevated LDL cholesterol levels. The name refers to their target molecule: Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) – an enzyme that plays a key role in cholesterol metabolism. PCSK9 inhibitors are among the most powerful LDL-lowering therapies currently available and are used especially in patients who cannot achieve adequate cholesterol control with statins alone.

Mechanism of Action

The liver uses LDL receptors on its surface to absorb LDL cholesterol from the bloodstream, thereby regulating cholesterol levels. The enzyme PCSK9 binds to these receptors and causes them to be degraded – resulting in fewer receptors and higher LDL levels in the blood.

PCSK9 inhibitors block this process: they bind to PCSK9 and prevent the enzyme from destroying the LDL receptors. This leads to a higher number of active LDL receptors on liver cells, causing a significant reduction in blood LDL cholesterol – by up to 60–70% in clinical studies.

Indications

PCSK9 inhibitors are mainly used in the following situations:

Familial hypercholesterolaemia: a genetic disorder characterised by severely elevated LDL cholesterol
Statin intolerance: patients who cannot tolerate statins or for whom statins are contraindicated
Insufficient LDL reduction despite maximum statin and ezetimibe therapy
High cardiovascular risk: e.g. after a heart attack or stroke for secondary prevention

Available Agents

The following PCSK9 inhibitors are currently approved:

Evolocumab (Repatha®): a monoclonal antibody administered as a subcutaneous injection every 2 or 4 weeks
Alirocumab (Praluent®): a monoclonal antibody administered as a subcutaneous injection every 2 or 4 weeks
Inclisiran (Leqvio®): a small interfering RNA (siRNA) molecule that inhibits PCSK9 production in the liver; administered twice yearly

Dosage and Administration

PCSK9 inhibitors are given as subcutaneous injections, meaning they are injected under the skin. Patients can self-administer the injection using a pre-filled pen or syringe. Dosing intervals vary depending on the agent:

Evolocumab and Alirocumab: every 2 or 4 weeks
Inclisiran: twice yearly (after an initial dose and a second dose at 3 months)

Side Effects

PCSK9 inhibitors are generally well tolerated. The most common side effects include:

Local injection site reactions (redness, swelling, pain)
Nasopharyngitis (cold-like symptoms)
Back pain
In rare cases: neurocognitive effects (e.g. memory disturbances – not conclusively proven)

Unlike statins, PCSK9 inhibitors do not cause muscle pain (myopathy), making them particularly suitable for statin-intolerant patients.

Clinical Evidence

The efficacy of PCSK9 inhibitors is well supported by large clinical trials:

The FOURIER trial demonstrated that evolocumab significantly reduced the risk of heart attack and stroke in patients with established cardiovascular disease.
The ODYSSEY OUTCOMES trial showed comparable results for alirocumab following acute coronary syndrome.

Coverage and Reimbursement

Due to the high cost of therapy, the prescription of PCSK9 inhibitors is subject to specific criteria in many countries. Health insurers typically reimburse the costs only in patients with documented familial hypercholesterolaemia or those at very high cardiovascular risk who have not reached LDL targets despite guideline-directed therapy.

References

Sabatine MS et al. - Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (FOURIER Trial). New England Journal of Medicine, 2017.
Schwartz GG et al. - Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (ODYSSEY OUTCOMES). New England Journal of Medicine, 2018.
Mach F et al. - 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal, 2020.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.